CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$22.09
−0.32%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +6.2%
- EBIT
- +5.5%
- EPS
- +4.3%
- Free cash flow
- +7.1%
- Operating cash flow
- +7.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +9.7%
- EPS
- +9.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -31.4%
- EBIT
- -22.7%
- Net income
- -31.4%
- EPS
- -19.6%
- Free cash flow
- -21.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026